Results 51 to 60 of about 168,585 (146)

Oscillatory dynamics in paclitaxel-proteinoid networks

Discover Molecules
Paclitaxel is a widely used microtubule-targeting chemotherapeutic, yet its intrinsic electrochemical behavior remains poorly understood. Here we investigate the electrochemical and oscillatory properties of paclitaxel incorporated into proteinoid ...
Panagiotis Mougkogiannis, Andrew Adamatzky   +1 more
doaj   +1 more source

Comparison of the Clinical Effects of Paclitaxel and Paclitaxel plus Oxaliplatin as the Second-line Treatment of Advanced Non-small Cell Lung Cancer

Chinese Journal of Lung Cancer, 2009
Background and objective Second-line chemotherapy with taxanes for the patients with non-small cell lung cancer (NSCLC), who had disease recurrence or failure in previously treated with platinum-based chemotherapy, has been shown to be effective. Besides
Tianqing CHU, Hao LIN, Jie SHEN, Runbo ZHONG, Baohui HAN   +4 more
doaj  

Beyond STMN1: stathmin-family control of microtubule dynamics and paclitaxel resistance in cancer. [PDF]

Front Oncol
Li H, Shi L, Wang Q, Han W.
europepmc   +1 more source

Impact of SLCO1B3 767G>C (rs60140950) polymorphism on paclitaxel response in Iraqi women with breast cancer. [PDF]

J Taibah Univ Med Sci
Al-Hussein BSJ, Al-Juhaishi AMR, Abo Almaali HMM, Alaskari AAJ.   +3 more
europepmc   +1 more source

Integrated Computational Modeling Reveals a Structurally Plausible Transient Paclitaxel-NK2R Interaction. [PDF]

Bioengineering (Basel)
Duda-Seiman C, Tartau LM, Hoinoiu B, Pit D, Dumitrascu V, Tanase AD, Rusu E, Luca A, Popa EG, Hoinoiu T.   +9 more
europepmc   +1 more source

Paclitaxel oral solution versus paclitaxel injection as second-line therapy for advanced gastric cancer: a multicenter, open-label, randomized phase III trial. [PDF]

ESMO Open
Li J, Huang M, Deng T, Bai Y, Liu T, Pan Y, Yu J, Pan H, Xu H, Wang J, Ye F, Wang J, Wu J, Cang S, Chen K, Zhang J, Zhang J, Ling Y, Zhong H, Fu G, Liu H, Huang L, Pan Y, Zhang L, Liu L, Ye X, Wu M, Zheng Z, Huang J, Liang X, Liu Y, Ding Y, Bai C, Yang L, Yan P, Miao J, Lu H, Bi Q, Zhou Y, Peng Y, Lin H, Deng Y, Zhong D, Gao C, Liu H, Tan S, Yi T, Liu Y, Song L, Chen Y, Qin S.   +50 more
europepmc   +1 more source

New CT-Detected Pulmonary Abnormalities During Breast Cancer Chemotherapy: Frequency, Imaging Features, and Cumulative-Exposure Associations. [PDF]

Cancers (Basel)
Zhao J, Kong X, Lin T, Hu L, He Y, Fan Z, Yang Y.   +6 more
europepmc   +1 more source

Matching-adjusted indirect comparison of fruquintinib versus ramucirumab in advanced gastric or gastroesophageal junction adenocarcinoma. [PDF]

J Comp Eff Res
An N, Chen J, Li J, Shen L, Guo W, Liu T, Li J, Qin S, Bai Y, Chen Z, Wang J, Pan Y, Xu R, Wang F.   +13 more
europepmc   +1 more source

[¹⁷⁷Lu]Lu-AKIR001 for CD44v6-Positive Pancreatic Cancer: Preclinical Efficacy and Combination Strategies. [PDF]

J Nucl Med
Gustafsson A, Svedberg H, Rinne SS, Bertilsson F, Selvaraju RK, Lundgren Mortensen AC, Lindskog C, Nestor M.   +7 more
europepmc   +1 more source

ANXA1/FPR Signaling Contribute to Paclitaxel Resistance in Ovarian Cancer Through PI3K/AKT-Associated PGC1α Regulation. [PDF]

Cancer Rep (Hoboken)
Li Z, Mingrui J, Yueyang Z, Hang Q, Qing L, Xiaoyu Y, Huimei Y, Meihui X.   +7 more
europepmc   +1 more source